Reversion of Multidrug Resistance by SKI-II in SGC7901/DDP Cells and Exploration of Underlying Mechanisms |
Zhu, Zu-An
(Department of Gastroenterology, Affiliated Hospital of Xuzhou Medical College)
Zhu, Zheng-Qiu (Department of Medical Oncology, Affiliated Hospital of Xuzhou Medical College) Cai, Hong-Xing (Department of Forensic Medicine, Yancheng Health Professional Technology Institute) Liu, Ying (Department of Pathology, Xuzhou Medical College) |
1 | Andrieu-Abadie N, Levade T (2002). Sphingomyelin hydrolysis during apoptosis. Biochim Biophys Acta, 1585, 126-34. DOI |
2 | Bieberich E (2008). Ceramide signaling in cancer and stem cells. Future Lipidol, 3, 273-300. DOI |
3 | Bielawska A, Bielawski J, Szulc ZM, et al (2008). Novel analogs of d-e-MAPP and B13, Part 2: Signature effects on bioactive sphingolipids. Bioorg Med Chem, 16, 1032-45. DOI |
4 | Bonhoure E, Pchejetski D, Aouali N, et al (2006). Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia, 20, 95-102. DOI |
5 | Cuvillier O (2007). Sphingosine kinase-1-a potential therapeutic target in cancer. Anticancer Drugs, 18, 105-10. DOI |
6 | Cuvillier O (2008). Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin Ther Targets, 12 1009-20. DOI |
7 | Esteban V, Lorenzo O, Ruperez M (2004). Angiotensin II via ATI and AT2 receptor and NF-kappa B pathway, regulates the inflammatory response in unilateral ureteral obstruction. Am Sec Nephrol, 15, 1514-29. DOI |
8 | Fan, T-J, Han L-H, Cong R-S, et al (2005). Caspase family proteases and apoptosis. Acta Biochim Biophys Sin, 37, 719-27. DOI |
9 | French KJ, Schrecengost RS, Lee BD, et al (2003). Discovery and evaluation of inhibi-tors of human sphingosine kinase. Cancer Res, 63, 5962-9. |
10 | French KJ, Upson JJ, Keller SN, et al (2006). Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther, 318, 596-603. DOI |
11 | Guillermet-Guibert J, Davenne L, Pchejetski D, et al (2009). Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther, 8, 809-20. DOI |
12 | Herr DR, Chun J (2007). Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets, 8, 155-67. DOI |
13 | Huang Y, Sadee W (2006). Membrane transporters and channels in and -sensitivity of tumor cells. Cancer Lett, 239, 168-82. DOI |
14 | Johnson KR, Johnson KY, Crellin HG, et al (2005). Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem, 53, 1159-66. DOI |
15 | Kawamori T, Osta W, Johnson KR, et al (2006). Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J, 20, 386-8. DOI |
16 | Koberle B, Tomicic MT, Usanova S, et al (2010). Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta, 1806, 172-82. |
17 | Lee SY, Yuk DY, Song HS, et al (2008). Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB. Eur J Pharmacol, 582, 17-25. DOI |
18 | Lin CF, Chen CL, Chang WT, et al (2005). Bcl-2 rescues ceramide and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. Biol Chem, 280, 23758-65. DOI |
19 | Min J, Stegner AL, Alexander H, et al (2004). Overexpression of sphingosine-1-phosphate lyase or inhibition of sphingosine kinase in Dictyostelium discoideum results in a selective increase in sensitivity to platinum-based chemotherapy drugs. Eukaryot Cell, 3, 795-805. DOI |
20 | Misao J, Hayakawa Y, Ohno M, et al (1996). Expression of Bcl- 2 protein, an inhibitor of apoptosis and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation, 94, 1506-12. DOI |
21 | Pilorget A, Demeule M, Barakat S, et al (2007).Modulation of P-glycoprotein function by sphingosine kinase-1 in brain endothelial cells. J Neurochem, 100, 1203-10. DOI |
22 | Modrak DE, Gold DV, Goldenberg DM (2006). Sphingolipid targets in cancer therapy. Mol Cancer Ther, 5, 200-8. DOI |
23 | Pchejetski D, Doumerc N, Golzio M, et al (2008). Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther, 7, 1836-45. |
24 | Pchejetski D, Golzio M, Bonhoure E, et al (2005). Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.Cancer Res, 65, 11667-75. DOI |
25 | Reynolds CP, Maurer BJ, Kolesnick RN (2004). Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett, 206, 169-80. DOI ScienceOn |
26 | Szulc ZM, Bielawski J, Gracz H, et al (2006). Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem, 14, 7083-104. DOI |
27 | Tsujimoto Y (2002). Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep, 22, 47-58. DOI ScienceOn |
28 | Van Brocklyn JR, Jackson CA, Pearl DK, et al (2005). Sphingosine kinase-1 expression correlates with poor survival ofpatients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol, 64, 695-705. DOI |
29 | Veldman RJ, Zerp S, van Blitterswijk WJ, et al (2004). N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. Br Cancer, 90, 917-25. DOI |
30 | Xie Z, Koyama T, Suzuki J, et al (2001). Coronary reperfusion following ischemia: different expression of bcl-2 and bax protein, and cardiomyocyte apoptosis. Jpn Heart, 42, 759-70. DOI |